New Evidence in Excessive Daytime Sleepiness Management: Meeting the Challenge to Provide Optimal Treatment

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2022 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 1, 2022, to August 1, 2023

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Jazz Pharmaceuticals

Excessive daytime sleepiness (EDS) is a common complaint in individuals with obstructive sleep apnea (OSA) and narcolepsy. Consequences of EDS include decreased cognitive functioning, work productivity, and quality of life, and increased risk for occupational and motor vehicle accidents. When factors such as treatment adherence, medications, comorbid illness, and inadequate sleep duration are controlled for, EDS is still reported in up to 6% to 18% of people treated for sleep disorders, with EDS being a persistent symptom. For most people, mild sleepiness is apparent only during boring, sedentary situations, however patients with narcolepsy, severe EDS, lead to involuntary somnolence during regular activities that could put the patient and others in a harmful situation, such as driving, eating, or talking.

Narcolepsy and OSA can interfere with psychological, social, and cognitive function and development and can inhibit academic, work, and social activities. With the potential danger surrounding narcoleptic patients, it is important for clinicians to understand and identify major sleep disorders and the best methods to diagnose and treat them. Greater awareness of sleep disorders and its symptoms can help accurately and efficiently diagnosis the disease. As research continues to grow, better treatments for narcolepsy are becoming available. Sleep studies are an essential part of the evaluation and diagnosis of patients with narcolepsy. While in most instances imaging studies do not give an accurate picture of what is going on, a few studies done with an MRI can show structural abnormalities of the brain that will help show what may be the underlying cause of the sleep disorder. Symptoms can include EDS, sleep paralysis, hallucinations, but cataplexy is the most specific symptom and occurs in almost no other diseases. The combination of an overnight polysomnogram (PSG) followed by a multiple sleep latency test (MSLT) can provide the proper evidence of narcolepsy while excluding other sleep disorders.

Upon completion of this activity, participants will be able to:

  • Review the prevalence and impact of excessive daytime sleepiness (EDS) and the burden that it places on patients suffering from psychiatric disorders

  • Assess the diagnostic tools for the identification and assessment of EDS in patients with psychiatric disorders

  • Analyze the latest data on the efficacy and safety of available and emerging therapies in improving outcomes for EDS patients with narcolepsy or obstructive sleep apnea

  • Discuss the role of a multidisciplinary team to better communicate the goals of treatment and utilize a shared decision-making approach to optimize therapeutic outcomes

  • Evaluate an evidence-based strategy to manage EDS in the context of psychiatric practice utilizing general medical, cognitive/behavioral, and pharmacologic techniques

  • Describe different considerations involving clinical pathways and site of care initiatives for optimal cost management and improved outcomes in EDS


Faculty: Michael J Thorpy, MD
Professor of Neurology
Albert Einstein College of Medicine
Director, Sleep-Wake Disorders Center
Montefiore Medical Center


(Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Thorpy has served as a consultant for Axsome, Balance Therapeutics, Flamel/Avadel, Jazz Pharmaceuticals, Suven Life Sciences Ltd., Idorsia Pharmaceuticals and Eisai Pharmaceuticals, Takeda Pharmaceutical Co., Ltd, NLS Pharmaceuticals, XW Pharma, Harmony Biosciences, LLC, Jazz Pharmaceuticals. His presentation has been reviewed for any bias.
Planning Committee: Bill Williams, MD has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jeremy Williams has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Jazz Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue